Compare Nokia Corp (NOK) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nokia Corp vs ResMed Inc. — how do they compare? Nokia Corp trades at $10.34 (market cap $56.99B), while ResMed Inc. trades at $231.16 (market cap $31.89B). The key difference: Nokia Corp is the larger of the two by market cap, and Nokia Corp pays the higher dividend (1.61%). Which is the better fit depends on your goals — on Pluang, investors hold Nokia Corp for 66 Days and ResMed Inc. for 51 Days on average.
| NOK | RMD | |
|---|---|---|
Market Cap | $56.99B | $31.89B |
Volume | 69,968,204 | 618,314 |
Sector | Technology | Health |
52-Week High | $16.83 | $277.88 |
52-Week Low | $5.18 | $182.82 |
Typical Hold Time | 66 Days | 51 Days |
Enterprise Value | $55.01B | $31.24B |
Dividend Yield | 1.61% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Nokia (NOK) trades at $10.285, down 3.15% today, with a bearish technical signal from moving averages and neutral oscillators. The company reported mixed quarterly earnings, beating in Q4 2025 and Q2 2026 but missing in Q1 2026. Revenue for 2025 was $19.89B with a net income margin of 3.47%. Recent news highlights partnerships in AI and satellite communications, including an expanded collaboration with Microsoft and a defense-focused satellite venture with ICEYE.
The stock presents a valuation challenge with a high P/E of 75.09, though analyst consensus is bullish with a $17.50 price target. Upside potential is supported by AI infrastructure demand and strategic partnerships, but risks include competitive pressures, execution on growth initiatives, and volatile cash flows. The current price is well below the consensus target, indicating significant projected upside if growth catalysts materialize.
ResMed (RMD) trades at $230.91, up 2.18% today, with a bullish technical signal and strong fundamentals. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $2.68. Revenue grew to $5.15B in 2025, with a net income margin of 26.94%. Analyst consensus is a buy, with a $242.70 price target. Recent news highlights EPS growth targets of 12%-14% and participation in investor conferences.
Outlook is positive due to robust earnings growth and market share gains, but risks include competitive pressures and regulatory investigations. The stock offers upside to the consensus target, supported by institutional buying and solid cash flow generation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
